Novo Nordisk, the maker of Wegovy and Ozempic, has filed a lawsuit against Hims & Hers, alleging that the virtual care company sold unapproved compounded versions of semaglutide in the United States and infringed Novo’s U.S. patents. Novo says the products are not FDA-approved and claims the way they were presented to consumers created safety risks and confusion.
What Novo Nordisk alleges in the lawsuit
what-novo-nordisk-alleges-in-the-lawsuitAccording to the report, Novo argues that Hims & Hers marketed compounded semaglutide as a safe alternative to Novo’s FDA-approved drugs. Novo claims these compounded versions may contain dangerous impurities or incorrect ingredient levels and that such issues could lead to immune reactions, overdoses, or hospitalizations. Novo is seeking damages and is also asking a court to permanently block Hims & Hers from selling compounded drugs that Novo says infringe its patents.
The broader timeline: pill announcement, federal scrutiny, and pullback
the-broader-timeline-pill-announcement-federal-scrutiny-and-pullback
The report says Hims & Hers announced on Feb. 5 that providers on its platform would have the option to prescribe a once-a-day compounded semaglutide pill for weight loss, described as having “the same active ingredients as Wegovy.”
On Feb. 6, the general counsel for the Department of Health and Human Services posted that the office referred Hims & Hers to the Department of Justice for investigation of potential violations of the Federal Food, Drug, and Cosmetic Act and related provisions. That same day, the FDA released a statement saying it planned to take action, emphasizing that compounded drug products are not FDA-approved and raising concerns that the company’s marketing implied equivalence with FDA-approved drugs.
The FDA statement, as quoted in the report, said Hims & Hers’ claims about compounded semaglutide products were false or misleading under specific sections of the law and that this resulted in products being introduced into interstate commerce in violation of the Act. The FDA gave the company 15 working days to respond.
On Feb. 7, the report says Hims & Hers posted that it would stop offering the compounded semaglutide pill after “constructive conversations with stakeholders across the industry.”
How Hims & Hers responded publicly
how-hims--hers-responded-publiclyIn response to questions from the outlet, Hims & Hers pointed to a post on X. In that post, the company characterized the lawsuit as an attack on compounded medications and argued that compounded drugs are a vital part of U.S. pharmacy practice, describing its role as providing access to personalized care. The company said it would continue to fight for choice, affordability, and access.
A partnership that later unraveled
a-partnership-that-later-unraveledThe report notes that in April of last year, Hims & Hers and Novo Nordisk announced a partnership offering access to Wegovy bundled with a Hims & Hers membership starting at $599 per month, which included 24/7 care, nutrition guidance, and clinical support. Hims & Hers began offering Wegovy to cash-paying patients with a prescription shortly after.
In June, Novo Nordisk said it was terminating its contract with Hims & Hers, citing concerns about “illegal mass compounding and deceptive marketing.” Novo alleged Hims & Hers was violating federal law by selling compounded versions at scale under the pretense of personalization and said the company’s marketing put patient safety at risk.
Hims & Hers CEO Andrew Dudum responded on X, saying the company was disappointed by what it described as misleading public messaging. He wrote that Novo’s commercial team had pressured Hims & Hers to steer patients toward Wegovy, and said the company refused what it described as anti-competitive demands that could interfere with provider independence and patient choice. Hims & Hers also posted on LinkedIn that it viewed the dispute as an attempt to challenge lawful personalized compounded care and warned against conflating lawful compounders with bad actors.
Market reaction mentioned in the report
market-reaction-mentioned-in-the-reportAfter news of the lawsuit, the report says Novo Nordisk’s stock rose about 3% to around $49.11 per share, while Hims & Hers’ stock fell around 21% to around $18.16 per share.
For patients seeking weight loss or diabetes-related care involving semaglutide, the report highlights a safety and clarity dispute: Novo alleges compounded products may vary in purity or ingredient levels and says Hims & Hers marketed them as safe alternatives to FDA-approved drugs. The FDA’s statement and timeline described in the report may also affect how patients evaluate product claims, especially when a service implies equivalence with approved medicines.
For medical tourism and cross-border care planning, the story underscores the importance of understanding what is FDA-approved versus compounded and how treatment access is delivered through direct-to-consumer platforms. Patients comparing options may weigh regulatory status, consistency of product formulation, and follow-up support models referenced in the report.
FAQs
faqs-Q1: What is Novo Nordisk alleging against Hims & Hers?
The report says Novo claims Hims & Hers sold unapproved compounded versions of semaglutide in the U.S., infringed Novo’s patents, and misled consumers and health professionals about safety.
Q2: Why does Novo Nordisk say compounded semaglutide could be risky?
Novo alleges the compounded products may contain dangerous impurities or incorrect ingredient levels, posing risks such as immune reactions, overdoses, or hospitalizations.
Q3: What did the FDA say about Hims & Hers and compounded semaglutide?
The report says the FDA stated compounded products are not FDA-approved and that Hims & Hers’ marketing implied the products were the same as FDA-approved drugs when they are not. The FDA gave the company 15 working days to respond.
Q4: Did Hims & Hers stop offering its compounded semaglutide pill?
Yes. The report says Hims & Hers posted that it would stop offering the compounded semaglutide pill after “constructive conversations with stakeholders across the industry.”
Q5: Were Novo Nordisk and Hims & Hers previously partners?
Yes. The report describes a partnership announced in April of last year that offered access to Wegovy with a Hims & Hers membership starting at $599 per month, later terminated by Novo Nordisk in June.
Medical Disclaimer
medical-disclaimer-“This content is for informational purposes only and does not replace professional medical advice.”